**Tab.S1** Characteristics for molecular subgroups shown in figure 3

|  |  |  |
| --- | --- | --- |
| **General characteristics** | IDH-mut astrocytoma  | IDH-mut oligodendroglioma |
| Radiotherapy |  |  |
| n | 16 | 17 |
| Median age (years) | 34 | 46 |
| WHO grade II/III (%) | 44/56 | 47/53 |
| Resection (%) | 63 | 65 |
| Median TTF *95%-CI* (years) | 2.0*0.0-4.9* | 7.3*3.7-9.6* |
| Median survival *95%-CI* (years) | 12.1*2.8-21.4* | n.r. |
| Temozolomide |  |  |
| n | 16 | 31 |
| Median age (years) | 34 | 46 |
| WHO grade II/III (%) | 62/38 | 35/65 |
| Resection (%) | 56 | 71 |
| Median TTF*95%-CI* (years) | 2.3*1.5-3.1* | 3.8*2.6-4.9* |
| Median survival *95%-CI* (years) | 6.1*4.0-8.2* | 9.8*6.7-12.9* |
| Radiotherapy + Temozolomide |  |  |
| n | 25 | 12 |
| Median age (years) | 38 | 47 |
| WHO grade II/III (%) | 36/64 | 25/75 |
| Resection (%) | 72 | 75 |
| Median TTF *95%-CI* (years) | 6.6*3.7-9.6* | n.r. |
| Median survival*95%-CI* (years) | 8.4*5.3-11.6* | n.r. |

*TTF* = time to treatment failure; *95%-CI* = 95% confidence interval; n.r. = not reached